Cargando…

Can Monoclonal Antibodies against CGRP Offer New Treatment Options for Type 2 Diabetes?

Detalles Bibliográficos
Autor principal:	Riera, Celine E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889048/ https://www.ncbi.nlm.nih.gov/pubmed/33604590 http://dx.doi.org/10.33696/diabetes.1.028

Ejemplares similares

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine
por: Lovato, Andrea, et al.
Publicado: (2023)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
por: Han, Lin, et al.
Publicado: (2019)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

Inflammatory complications of CGRP monoclonal antibodies: a case series
por: Ray, Jason C., et al.
Publicado: (2021)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
por: Sevivas, Hugo, et al.
Publicado: (2022)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review
por: Aditya, Suruchi, et al.
Publicado: (2023)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

In vitro characterization of AA71, a potent and selective human monoclonal antibody against CGRP receptor
por: Shi, L, et al.
Publicado: (2013)

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
por: Vandervorst, Fenne, et al.
Publicado: (2021)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review
por: Albanese, Maria, et al.
Publicado: (2022)

A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
por: Kielbasa, William, et al.
Publicado: (2019)

EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor
por: Xu, C, et al.
Publicado: (2014)

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
por: Mullin, Kathleen, et al.
Publicado: (2020)

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
por: Hong, Ja Bin, et al.
Publicado: (2023)

Characterization of transit rates in the large intestine of mice following treatment with a CGRP antibody, CGRP receptor antibody, and small molecule CGRP receptor antagonists
por: Johnson, Kirk W., et al.
Publicado: (2022)

Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study
por: Basedau, Hauke, et al.
Publicado: (2022)

Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
por: Kaltseis, Katharina, et al.
Publicado: (2023)

Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
por: Vandenbussche, Nicolas, et al.
Publicado: (2023)

An update to monoclonal antibody as therapeutic option against COVID-19
por: Deb, Paroma, et al.
Publicado: (2021)

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
por: Vernieri, Fabrizio, et al.
Publicado: (2021)

Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
por: Haanes, Kristian Agmund, et al.
Publicado: (2020)

What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
por: Waliszewska-Prosół, Marta, et al.
Publicado: (2023)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Monoclonal therapy against calcitonin gene-related peptide lowers hyperglycemia and adiposity in type 2 diabetes mouse models
por: Halloran, Jonathan, et al.
Publicado: (2020)

Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review
por: Rhyne, Christopher, et al.
Publicado: (2023)

Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis
por: Overeem, Lucas Hendrik, et al.
Publicado: (2021)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
por: Monteith, David, et al.
Publicado: (2017)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
por: Cohen, Fred, et al.
Publicado: (2022)

Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache
por: Pensato, Umberto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rf6u8c3aa44v1q2vmhkb4jh1sv